871269-10-2

Basic information

• Product Name: N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE
• Synonyms: N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE;N-Cyclohexyl 3-bromophenylsulfonamide
• CAS NO: 871269-10-2
• Molecular Formula: C12H16BrNO2S
• Molecular Weight: 318.23
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 871269-10-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE(871269-10-2)
• EPA Substance Registry System: N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE(871269-10-2)

Safety Data

• Hazardous Substances Data: 871269-10-2(Hazardous Substances Data)

Usage

General Description

N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE is a chemical compound that belongs to the class of sulfonamides, which are a group of organic compounds containing a sulfur atom with a central nitrogen atom. It is derived from 3-bromobenzenesulfonamide and cyclohexylamine, and its molecular structure consists of a benzene ring with a bromine and sulfonamide group attached to it, as well as a cyclohexyl group. N-CYCLOHEXYL 3-BROMOBENZENESULFONAMIDE has potential applications in the pharmaceutical and agrochemical industries, as well as in the synthesis of other organic compounds. It may also have biological activity and be used as a reagent in chemical reactions.

Upstream product

• 89599-01-9 3-bromobenzenesulfonamide 
• 98-89-5 Cyclohexanecarboxylic acid 
• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 108-91-8 cyclohexylamine 

Relevant articles and documents

Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma

Growth, division, and development of healthy cells relies on efficient response to environmental survival cues. The conserved mitogen-activated protein kinase (MAPK) family of pathways interface extracellular stimuli to intracellular processes for this purpose. Within these pathways, the MEK family has been identified as a target of interest due to its clinical relevance. Particularly, MEK4 has drawn recent attention for its indications in pancreatic and prostate cancers. Here, we report two potent MEK4 inhibitors demonstrating significant reduction of phospho-JNK and antiproliferative properties against pancreatic cancer cell lines. Furthermore, molecular inhibition of MEK4 pathway activates the MEK1/2 pathway, with the combination of MEK1/2 and MEK4 inhibitors demonstrating synergistic effects against pancreatic cancer cells. Our inhibitors provided insight into the crosstalk between MAPK pathways and new tools for elucidating the roles of MEK4 in disease states, findings which will pave the way for better understanding of the MAPK pathways and development of additional probes.

SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed to a compound of Formula (XVI) wherein R, R2, R3, R4, R5, R6, R7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmac